TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27197662
Drug: FEX 60
Normalized name: Wal-Fex 60 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEX 60 mg with 300 mL of AJ
Study: 27197662
Drug: FEX 60
Normalized name: Wal-Fex 60 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEX 60 mg with 600 mL of AJ
Study: 18206190
Drug: Encapsulated L-phenylalanine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated L-phenylalanine (Phe) in the luteal phase for women in the higher 50th percentile of rigid restraint
Study: 18206190
Drug: Encapsulated L-phenylalanine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated L-phenylalanine (Phe)
Study: 8866639
Drug: Intracavernous injection
Normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernous injection of moxisylyte at 10 mg
Study: 8866639
Drug: Intracavernous injection
Normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernous injection of moxisylyte at 30 mg
Study: 15737519
Drug: Telithromycin 800
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telithromycin 800 mg for 5 days
Study: 9469269
Drug: Azithromycin, 1
Normalized name: Azithromycin, 1 g oral powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin, 1 g oral slurry in a single dose
Study: 9469269
Drug: Erythromycin, 500
Normalized name: Erythromycin, 500 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin, 500 mg every 6 hours for 7 days
Study: 31005336
Drug: BI 425809
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 425809 (10, 25, or 50 mg)
Study: 29091568
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ACE inhibitor and statin
Study: 23806287
Drug: Ambulatory oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambulatory oxygen at 4 L/min intranasally
Study: 23806287
Drug: Ambulatory air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambulatory air at 4 L/min intranasally
Study: 11763936
Drug: Colgate Winterfresh
Normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colgate Winterfresh Gel (1100 ppm F)
Study: 9001831
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg BID
Study: 8111819
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg QID
Study: 24808487
Drug: Lutein supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein supplement meal
Study: 24808487
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 29 SNPs in 15 genes
Study: 15790459
Drug: Paclitaxel 200
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 200 mg/m² IV infusion on day 1, Carboplatin AUC 6.0 IV on day 1, Etoposide 50 mg alternating with 100 mg orally on days 1-10, 6 courses at 21-day intervals
Study: 10498115
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation at a dosage of 500 to 1,000 mg per day
Study: 7585298
Drug: Liquid supplement
Normalized name: Clear liquid supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid supplement containing fat (30 to 36 g) and cholesterol (650 to 780 mg)
Study: 7585298
Drug: Liquid supplement
Normalized name: Clear liquid supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid supplement that was fat and cholesterol free
Study: 6263091
Drug: Lithium (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (300 mg three times daily for 18 days of every 21 day chemotherapy cycle)
Study: 24917273
Drug: Methotrexate (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (25 mg weekly)
Study: 22555266
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) in NYHA functional class III/IV
Study: 18846541
Drug: Amantadine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine (400 mg/day)
Study: 11840184
Drug: Tamarind (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamarind (10 g daily for 18 days)
Study: 30951624
Drug: Prosthetic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prosthetic treatment of missing teeth
Study: 30951624
Drug: Professional periodontal
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professional periodontal treatment
Study: 1805808
Drug: Sun E45
Normalized name: CLOZAPINE (SUN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sun E45 lotion SPF 15
Study: 31047857
Drug: Multidomain lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidomain lifestyle intervention (cognitive training, physical activity counseling, nutritional counseling) with omega-3 supplement for 3 years
Study: 22266897
Drug: Bupivacaine extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine extended-release (150, 300, 450, or 600 mg)
Study: 22266897
Drug: Bupivacaine HCl
Normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine HCl 150 mg with epinephrine
Study: 22266897
Drug: Bupivacaine extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine extended-release
Study: 9342068
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (AmBisome) 4 mg/kg daily for 3 weeks followed by fluconazole 400 mg daily for 7 weeks
Study: 30692242
Drug: Hybrid closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid closed-loop with standard strength insulin (U100)
Study: 30692242
Drug: Hybrid closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid closed-loop with diluted insulin (U20)
Study: 25499006
Drug: DCLHb (diasiirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCLHb (diasiirin cross-linked hemoglobin) as add-on therapy
Study: 23453111
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) 300 μg daily subcutaneous injection for 5 days
Study: 9743952
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HD-MTX) with reduced CRT (12 Gy for IR, 18 Gy for MR, and 18 Gy for HR)
Study: 9743952
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CRT (12 Gy) and HD-MTX in T-cell ALL patients
Study: 9743952
Drug: Intensive systemic
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive systemic and intrathecal chemotherapy without CRT in low-risk ALL patients
Study: 3183370
Drug: xipamide 20
Normalized name: xipamide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: xipamide 20 mg once a day
Study: 22067185
Drug: Bupivacaine extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine extended-release 300 mg
Study: 3087656
Drug: Astemizole 10
Normalized name: astemizole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole 10 mg orally per day
Study: 3087656
Drug: Beclomethasone 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone 100 micrograms in each nostril twice daily
Study: 17327934
Drug: Lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 15 mg
Study: 20384961
Drug: Ribavirin concentration
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin concentration <2 mg/L at day 29
Study: 20384961
Drug: 12-week treatment
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week treatment group with ribavirin concentration ≥2 mg/L
Study: 20384961
Drug: 12-week treatment
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week treatment group with ribavirin concentration <2 mg/L
Study: 20384961
Drug: 24-week treatment
Normalized name: Weeks and Leo Complete Lice Treatment KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-week treatment group with ribavirin concentration ≥2 mg/L
Study: 20384961
Drug: 24-week treatment
Normalized name: Weeks and Leo Complete Lice Treatment KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-week treatment group with ribavirin concentration <2 mg/L
Study: 19055294
Drug: Zinc oxide
Normalized name: Zinc Oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc oxide sticking tablets at the same acupoints
Study: 8217176
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg of ondansetron
Study: 27066461
Drug: Continuous antibiotic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous antibiotic prophylaxis (CAP)
Study: 21429706
Drug: Home-based constraint-induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based constraint-induced therapy (CIT)
Study: 21429706
Drug: Dose-matched home-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-matched home-based control intervention
Study: 6400709
Drug: Acarbose 100
Normalized name: acarbose 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 100 mg before the evening meal
Study: 3915888
Drug: Tenoxicam 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 40 mg/day
Study: 3915888
Drug: Piroxicam 40
Normalized name: piroxicam 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 40 mg/day
Study: 28735464
Drug: High-dose protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose protocol
Study: 28735464
Drug: Low-dose protocol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose protocol
Study: 24065010
Drug: Pump-only therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pump-only therapy (standard insulin pump)
Study: 18294116
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with perindopril and indapamide
Study: 11808057
Drug: 10% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% chlorhexidine varnish treatment
Study: 9209249
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg glyburide
Study: 9209249
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg minoxidil with 2.5 mg glyburide
Study: 17628384
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg glyburide
Study: 9209249
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg glyburide with 5 mg minoxidil
Study: 31096794
Drug: Microneedling with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microneedling with topical bleomycin at 2 weeks interval
Study: 1640303
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antibiotic treatment)
Study: 3513752
Drug: Methamphetamine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methamphetamine (20 mg)
Study: 19916063
Drug: Methamphetamine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methamphetamine (40 mg)
Study: 1971862
Drug: Gabapentin 1200
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 1200 mg/day
Study: 11690735
Drug: Gabapentin 1800
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 1800 mg/day
Study: 16879931
Drug: Gabapentin 2400
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 2400 mg/day
Study: 18070144
Drug: Control (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (250 ml of 0.9% sodium chloride)
Study: 16480969
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy alone in Group B
Study: 16480969
Drug: Atorvastatin vs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin vs Conventional therapy alone
Study: 8924191
Drug: Phentermine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentermine (30 mg)
Study: 4317858
Drug: Fenfluramine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine (40 mg)
Study: 8924191
Drug: d-Amphetamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-Amphetamine (10 mg)
Study: 3933028
Drug: d-Amphetamine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-Amphetamine (20 mg)
Study: 8924191
Drug: Fenfluramine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine (80 mg)
Study: 24377403
Drug: Psychological therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological therapies (Cognitive Behavioral Therapy and Psychoanalytic Therapy)
Study: 22094261
Drug: Preemptive morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive morphine analgesia (maximum of 14 days)
Study: 15100699
Drug: Lamotrigine (LTG)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) 325 mg
Study: 12387693
Drug: Antibiotics (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (specific type not mentioned)
Study: 2008942
Drug: Ropivacaine 0.5%
Normalized name: ROPivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.5% (175 mg)
Study: 2008942
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% (175 mg)
Study: 7261830
Drug: Antacid foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid foam tablets
Study: 24089377
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (BR) supplementation (140 ml/day, containing 8 mmol of NO3(‐))
Study: 18505948
Drug: Problem-solving therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving therapy
Study: 17915638
Drug: Helicidum tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helicidum tablet preparation 2 (75 mg, 3 tablets)
Study: 25204507
Drug: 0.5 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 μg/kg of dexmedetomidine (subclinical dose group)
Study: 25204507
Drug: 1.0 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 μg/kg of dexmedetomidine (clinical dose group)
Study: 11049764
Drug: Amoxicillin/clavulanate
Normalized name: AMOXICILLIN/CLAVULANATE
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate
Study: 27151024
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human thrombopoietin (rhTPO) at a dose of 300 U/(kg·d) for a maximum of 14 days
Study: 27151024
Drug: Glucocorticoid (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid (standard dose) for 28 days
Study: 17721372
Drug: Epaxal coadministered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epaxal coadministered with DTPaHibIPV, oral polio vaccine, and measles‐mumps‐rubella vaccine (group A)
Study: 17721372
Drug: Havrix Junior
Normalized name: Havrix
DrugBank: Hepatitis A Vaccine (DB10989)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Havrix Junior coadministered with DTPaHibIPV, oral polio vaccine, and measles‐mumps‐rubella vaccine (group C)
Study: 17721372
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose for all groups
Study: 15298633
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg twice daily
Study: 22700038
Drug: MDMA (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (125 mg)
Study: 30942011
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional treatment only).
Study: 26156796
Drug: Butyrate enema
Normalized name: butyrate
DrugBank: Butyric Acid (DB03568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butyrate enema (100 mmol sodium butyrate/L; 60 mL; n = 7)
Study: 26156796
Drug: Placebo (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (140 mmol 0.9% NaCl/L; 60 mL; n = 5)
Study: 22496275
Drug: Preventive medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive medications (statins, antiplatelet therapy, beta-blockers, ACE inhibitors/ARBs)
Study: 21899544
Drug: Methylsulfonylmethane (MSM)
DrugBank: Dimethyl sulfone (DB14090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylsulfonylmethane (MSM) supplementation (50 mg/kg body weight)
Study: 18179672
Drug: Schema Focused
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schema Focused Therapy (SFT)
Study: 10808734
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate 10 mg
Study: 11070759
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate 40 mg-SR
Study: 11070759
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate 80 mg-SR
Study: 1571421
Drug: Renal ultrasonography
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal ultrasonography after antimicrobial therapy
Study: 31335641
Drug: Hybrid emotion-focused
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid emotion-focused exposure treatment (n = 58, 10-16 sessions)
Study: 31335641
Drug: iCBT (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: iCBT (n = 57; 8 treatment modules)
Study: 30113526
Drug: Perindopril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (10 mg daily)
Study: 12937228
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg daily)
Study: 22901886
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg mepolizumab
Study: 18085837
Drug: IANB plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: IANB plus mock buccal infiltration and lingual infiltration
Study: 16260891
Drug: Indomethacin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (0.2 mg/kg, three doses at 12-hour intervals, infused continuously over 15 min)
Study: 16260891
Drug: Ibuprofen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (10 mg/kg initial dose followed by two doses of 5 mg/kg each after 24 and 48 h, infused continuously over 15 min)
Study: 12226782
Drug: Real ESWT
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real ESWT (low-energy shock wave therapy)
Study: 11382863
Drug: Cholinergic REM
Normalized name: carbamide peroxide
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cholinergic REM sleep induction test (CRIT) with 10 mg galanthamine
Study: 25488686
Drug: docetaxel (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: docetaxel (35 mg/m² days 1, 8, 15 every 4 weeks for four or six cycles)
Study: 25488686
Drug: CMF (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF (cyclophosphamide 600 mg/m², methotrexate 40 mg/m², fluorouracil 600 mg/m², days 1, 8)
Study: 23352187
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (NS) injection plus PT
Study: 20919993
Drug: Selective iNOS
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selective iNOS inhibitor 1400W
Study: 19698147
Drug: Drug (positive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug (positive control) group
Study: 16424063
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea catechins (GTCs) - 600 mg/d (three capsules of 200 mg each)
Study: 30024811
Drug: Community Health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community Health Worker (CHW) intervention with cash incentives, supply chain support, and monthly clinical supervision.
Study: 19879276
Drug: Ceftriaxone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (1 x 2 g daily for 14 days)
Study: 19879276
Drug: Meropenem (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (3 x 1 g daily for 14 days)
Study: 16238119
Drug: Novo‐Helisen Depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novo‐Helisen Depot allergy vaccines for 3 years
Study: 16238119
Drug: Conventional methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional methods of treatment
Study: 10524722
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy over a period of 8 weeks
Study: 10524722
Drug: No changes
Approvals — FDA: no, EMA: no, PMDA: no
Description: No changes to treatment status (Control)
Study: 30318240
Drug: USG-guided SLN
Normalized name: naphazoline
DrugBank: Naphazoline (DB06711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: USG-guided SLN block bilaterally with 2.5 ml of 2% lignocaine along with GA (Group L)
Study: 27802910
Drug: Support therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Support therapy group (SG)
Study: 16460486
Drug: Silybum marianum
Normalized name: Silybum marianum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silybum marianum (600 mg or 1200 mg/day)
Study: 11571244
Drug: alpha‐galactosidase A
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha‐galactosidase A therapy
Study: 9610942
Drug: Zolpidem 10
Normalized name: zolpidem 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 10 mg with alcohol (0.75 g ethanol/kg b.wt.)
Study: 9610942
Drug: Zolpidem 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 15 mg with alcohol (0.75 g ethanol/kg b.wt.)